Please assess the completion status of the following clinical trial:

Trial Title: Induction of Labor in Pregnant Women With Prelabor Rupture of Membranes - Oxytocin or Misoprostol

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Gestational age (36-42 weeks).~* Prelabor rupture of membranes within the last 24hours~* Vertex presentation~Exclusion Criteria:~1. History of medical diseases (HTN, diabetes milletus, systemic lupus erythematosus, cardiac, etc.).~2. Antepartum hemorrhage~3. Chorioamnionitis / prelabor rupture of membranes \>24hours~4. Multiple pregnancy.~5. Abnormal fetal heart rate pattern upon admission~6. Intrauterine growth restriction~7. Fetal malpresentation.~8. Previous uterine scar.~9. Estimated fetal weight more than 4kg.~10. Patients already in labor~11. Contraindication for prostaglandin/oxytocin use (allergy,..)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- misoprostol group (Type: ACTIVE_COMPARATOR): 25µg misoprostol oral tablet every 4 hours with maximum200 µg
- oxytocin group (Type: ACTIVE_COMPARATOR): oxytocin infusion according to ASUMH local protocol: Put 3IU oxytocin (3000mIU) +50ml of normal saline in syringe pump= (60mIU/ml). Commence at 1ml/hour (1mIU/min) for 1/2 hour.~* If contractions inadequate +fetal monitor healthy 2 ml/hour for 1/2 hour.~* If contractions inadequate +fetal monitor healthy 4 ml/hour for 1/2 hour.~* If contractions inadequate +fetal monitor healthy 6 ml/hour for 1/2 hour.~* If contractions inadequate +fetal monitor healthy increase by 2ml/hr. for max. 27ml/hour.~At any point there's fetal or maternal distress (e.g. pathological FHR pattern, antepartum hemorrhage, etc.) the study intervention will be stopped, and the maternal/fetal condition will be managed by cesarean section.

Based on this trial design, predict the completion outcome and termination type (if applicable).